ARK Genomic Revolution ETF Newsroom

Craig-Hallum Maintains Schrodinger(SDGR.US) With Buy Rating

Moomoo NewsJul 29 09:35 ET

Craig-Hallum Maintains Schrodinger(SDGR.US) With Buy Rating

Moomoo NewsJul 26 09:33 ET

Schrodinger (SDGR) Receives a Buy From Craig-Hallum

TipRanksJul 26 09:28 ET

Leerink Upgrades Ionis to Outperform, Cites Angelman Drug

Seeking AlphaJul 24 11:04 ET

Leerink Partners Upgrades Ionis Pharmaceuticals(IONS.US) to Buy Rating, Announces Target Price $62

Moomoo NewsJul 24 06:34 ET

Ionis Pharmaceuticals Price Target Raised to $68.00/Share From $67.00 by B of A Securities

Dow JonesJul 23 09:50 ET

A Quick Look at Today's Ratings for Ionis Pharmaceuticals(IONS.US), With a Forecast Between $48 to $82

Moomoo NewsJul 23 09:05 ET

Canaccord Genuity Adjusts Price Target on 10x Genomics to $32 From $50, Maintains Buy Rating

MT NewswiresJul 23 09:01 ET

TD Cowen Keeps Their Buy Rating on Ionis Pharmaceuticals (IONS)

TipRanksJul 23 07:54 ET

10x Genomics Analyst Ratings

BenzingaJul 23 07:44 ET

CCORF Maintains 10x Genomics(TXG.US) With Buy Rating, Cuts Target Price to $32

Moomoo NewsJul 23 07:41 ET

TD Cowen Maintains CRISPR Therapeutics(CRSP.US) With Sell Rating, Maintains Target Price $30

Moomoo NewsJul 23 07:33 ET

Beam Therapeutics Analyst Ratings

BenzingaJul 23 07:24 ET

H.C. Wainwright Initiates Beam Therapeutics(BEAM.US) With Buy Rating, Announces Target Price $80

Moomoo NewsJul 23 06:31 ET

Buy Rating on Ionis Pharmaceuticals Backed by Strong Trial Results for Angelman Syndrome Drug

TipRanksJul 23 06:29 ET

Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), Lifestance Health Group (LFST) and Agilent (A)

TipRanksJul 23 06:26 ET

Ionis Pharmaceuticals' ION582 Garners Buy Rating Amidst Promising Efficacy and Safety Data

TipRanksJul 23 05:01 ET

Ionis Pharmaceuticals Analyst Ratings

BenzingaJul 22 14:35 ET

10x Genomics Analyst Ratings

BenzingaJul 22 06:27 ET

10x Genomics Analyst Ratings

BenzingaJul 18 08:19 ET